Patents by Inventor Cheng San Brian Chia

Cheng San Brian Chia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic spalt-like transcription factor 4 (SALL4) peptide
    Patent number: 10793601
    Abstract: Isolated peptides and pharmaceutical compositions comprising isolated peptides that bind to retinoblastoma binding protein 4 (RBBp4) and block the Spalt-Like Transcription Factor 4 (SALL4)-RBBp4 interaction are described. Methods of inhibiting binding of SALL4 to RBBp4 and methods of treating a subject having a disorder mediated by a dysregulation of SALL4 are also described.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: October 6, 2020
    Assignees: National University of Singapore, The Brigham and Women's Hospital, Inc., Agency for Science, Technology and Research
    Inventors: Bee Hui Liu, Daniel Geoffrey Tenen, Li Chai, Cheng San Brian Chia, Anders Poulsen
  • Therapeutic SALL4 Peptide
    Publication number: 20190218253
    Abstract: The present invention provides, in certain embodiments, isolated peptides and pharmaceutical compositions comprising isolated peptides that bind to retinoblastoma binding protein 4 RBBp4 such that, the binding blocks the SALL4-RBBp4 interaction. Methods of inhibiting binding of SALL4 with RBBp4 and methods for treating a subject having a disorder mediated by a dysregulation of SALL4 are also provided.
    Type: Application
    Filed: April 28, 2017
    Publication date: July 18, 2019
    Inventors: Bee Hui Liu, Daniel Geoffrey Tenen, Li Chai, Cheng San Brian Chia, Anders Poulsen
  • COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS
    Publication number: 20190071416
    Abstract: Compounds For Inhibition Of Cancer and Epigenesis. The present invention relates to quinolines and 5,6,7,8-tetrahydroacridines of the formula (I) wherein Z1, Z2, X, R1 to R8 and Y are defined as described in the specification, or a pharmaceutically acceptable form or prodrug thereof, that are inhibitors of methyl transferases such as protein lysine methyltransferases and more particularly SMYD3. The present invention also relates to the methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with enzymes having methyl transferase activities/functions and/or via unspecified/multi-targeted mechanisms.
    Type: Application
    Filed: October 10, 2016
    Publication date: March 7, 2019
    Inventors: Klement Jihao Foo, Anders Poulsen, Thomas Hugo Keller, Si Si Liew, Cheng San Brian Chia, Jin Yan Melgious Ang, Chuhul Huang
  • EIF4E binding peptides
    Patent number: 9533023
    Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: January 3, 2017
    Assignee: Agency for Science, Technology and Research
    Inventors: Christopher John Brown, Cheng San Brian Chia
  • EIF4E BINDING PEPTIDES
    Publication number: 20160038567
    Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
    Type: Application
    Filed: March 31, 2015
    Publication date: February 11, 2016
    Inventors: Christopher John BROWN, Cheng San Brian Chia
  • eIF4E binding peptides
    Patent number: 9018348
    Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: April 28, 2015
    Assignee: Agency for Science, Technology and Research
    Inventors: Christopher John Brown, Cheng San Brian Chia
  • EIF4E BINDING PEPTIDES
    Publication number: 20130130989
    Abstract: The present invention relates to modified eIF4G1 peptides, uses thereof and pharmaceutical compositions comprising the modified eIF4G1 peptides.
    Type: Application
    Filed: April 27, 2011
    Publication date: May 23, 2013
    Inventors: Christopher John Brown, Cheng San Brian Chia